Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors.

Headache

Department of Psychiatry, Queen's University, and the Kingston Psychiatric Hospital, Kingston, Ontario, Canada.

Published: March 2000

We report the successful use of valproate in a 44-year-old woman with migraine induced by selective serotonin reuptake inhibitors. Valproate should be considered for those patients who develop serious migraine for the first time, or worsening of previous migraine, after the initiation of treatment with selective serotonin reuptake inhibitors and for whom continued treatment with this class of drugs is important.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1526-4610.2000.00036.xDOI Listing

Publication Analysis

Top Keywords

selective serotonin
12
serotonin reuptake
12
reuptake inhibitors
12
migraine induced
8
induced selective
8
valproate prophylaxis
4
migraine
4
prophylaxis migraine
4
inhibitors report
4
report successful
4

Similar Publications

Background: The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid function as measured by the National Newborn Screening (NBS) Program and identified contributory factors.

View Article and Find Full Text PDF

Antidepressants versus placebo for generalised anxiety disorder (GAD).

Cochrane Database Syst Rev

January 2025

Department of Psychiatry and Department of Epidemiology and Biostatistics, Western University, St Thomas, Canada.

Background: Generalised anxiety disorder (GAD) is a mental health condition characterised by excessive anxiety and worry about everyday events. GAD is a common disorder and generally affects women twice as often as men. Treatments include various psychological and pharmacological therapies.

View Article and Find Full Text PDF

Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction.

Front Psychiatry

January 2025

Xinjiang Clinical Medical Research Center of Mental Health, The Psychological Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

Behavioral addictive disorders (BADs) have become a significant societal challenge over time. The central feature of BADs is the loss of control over engaging in and continuing behaviors, even when facing negative consequences. The neurobiological underpinnings of BADs primarily involve impairments in the reward circuitry, encompassing the ventral tegmental area, nucleus accumbens in the ventral striatum, and prefrontal cortex.

View Article and Find Full Text PDF

Thyroid Endocrine Disrupting Potential of Fluoxetine in Zebrafish Larvae.

J Appl Toxicol

January 2025

Changjiang Basin Ecology and Environment Monitoring and Scientific Research Center, Changjiang Basin Ecology and Environment Administration, Ministry of Ecology and Environment, Wuhan, China.

Fluoxetine (FLX), a typical selective serotonin reuptake inhibitors, has been frequently detected in aquatic environment and wild fish. However, little is known about its effect on thyroid endocrine system. In the present study, zebrafish (Danio rerio) embryos were exposed to 1, 3, 10, and 30 μg/L of FLX for 6 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!